A phase 1 study of SMAR-T cells
Latest Information Update: 19 Apr 2023
At a glance
- Drugs RNA-enabled-T-cell-therapies-Geneius-Biotechnology (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions
- 19 Apr 2023 New trial record
- 14 Apr 2023 According to a Geneius Biotechnology media release, company will collaborate with Yale (CT) and Mount Sinai (NY/NJ) to conduct clinical trial and the clinical data of this study is anticipated in 2024.